183 related articles for article (PubMed ID: 22008909)
1. Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.
Hine CM; Seluanov A; Gorbunova V
Mol Ther; 2012 Feb; 20(2):347-55. PubMed ID: 22008909
[TBL] [Abstract][Full Text] [Related]
2. Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy.
Chen Y; Li Z; Xu Z; Tang H; Guo W; Sun X; Zhang W; Zhang J; Wan X; Jiang Y; Mao Z
Cell Death Dis; 2018 Apr; 9(4):420. PubMed ID: 29549248
[TBL] [Abstract][Full Text] [Related]
3. Use of the Rad51 promoter for targeted anti-cancer therapy.
Hine CM; Seluanov A; Gorbunova V
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20810-5. PubMed ID: 19106292
[TBL] [Abstract][Full Text] [Related]
4. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.
Amit D; Hochberg A
J Transl Med; 2010 Dec; 8():134. PubMed ID: 21162716
[TBL] [Abstract][Full Text] [Related]
5. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.
Ito M; Yamamoto S; Nimura K; Hiraoka K; Tamai K; Kaneda Y
J Gene Med; 2005 Aug; 7(8):1044-52. PubMed ID: 15756713
[TBL] [Abstract][Full Text] [Related]
6. Utilization of Rad51C promoter for transcriptional targeting of cancer cells.
Cao Y; Xu Y; Zhang L; Li Z; Jiang Y; Tian X; Seluanov A; Gorbunova V; Mao Z
Oncotarget; 2014 Apr; 5(7):1805-11. PubMed ID: 24742710
[TBL] [Abstract][Full Text] [Related]
7. A polymer library approach to suicide gene therapy for cancer.
Anderson DG; Peng W; Akinc A; Hossain N; Kohn A; Padera R; Langer R; Sawicki JA
Proc Natl Acad Sci U S A; 2004 Nov; 101(45):16028-33. PubMed ID: 15520369
[TBL] [Abstract][Full Text] [Related]
8. A nanoparticle formulation that selectively transfects metastatic tumors in mice.
Yang J; Hendricks W; Liu G; McCaffery JM; Kinzler KW; Huso DL; Vogelstein B; Zhou S
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14717-22. PubMed ID: 23959886
[TBL] [Abstract][Full Text] [Related]
9. A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy.
Flentie K; Kocher B; Gammon ST; Novack DV; McKinney JS; Piwnica-Worms D
Cancer Discov; 2012 Jul; 2(7):624-37. PubMed ID: 22728436
[TBL] [Abstract][Full Text] [Related]
10. RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.
He WL; Li YH; Hou WJ; Ke ZF; Chen XL; Lu LY; Cai SR; Song W; Zhang CH; He YL
World J Gastroenterol; 2014 Aug; 20(29):10094-107. PubMed ID: 25110436
[TBL] [Abstract][Full Text] [Related]
11. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences.
Mizrahi A; Czerniak A; Levy T; Amiur S; Gallula J; Matouk I; Abu-lail R; Sorin V; Birman T; de Groot N; Hochberg A; Ohana P
J Transl Med; 2009 Aug; 7():69. PubMed ID: 19656414
[TBL] [Abstract][Full Text] [Related]
12. In vivo bioluminescence imaging of murine xenograft cancer models with a red-shifted thermostable luciferase.
Mezzanotte L; Fazzina R; Michelini E; Tonelli R; Pession A; Branchini B; Roda A
Mol Imaging Biol; 2010 Aug; 12(4):406-14. PubMed ID: 19937390
[TBL] [Abstract][Full Text] [Related]
13. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.
Cocco E; Deng Y; Shapiro EM; Bortolomai I; Lopez S; Lin K; Bellone S; Cui J; Menderes G; Black JD; Schwab CL; Bonazzoli E; Yang F; Predolini F; Zammataro L; Altwerger G; de Haydu C; Clark M; Alvarenga J; Ratner E; Azodi M; Silasi DA; Schwartz PE; Litkouhi B; Saltzman WM; Santin AD
Mol Cancer Ther; 2017 Feb; 16(2):323-333. PubMed ID: 27956521
[TBL] [Abstract][Full Text] [Related]
14. Safe and Efficacious Diphtheria Toxin-Based Treatment for Melanoma: Combination of a Light-On Gene-Expression System and Nanotechnology.
Xu J; He M; Hou X; Wang Y; Shou C; Cai X; Yuan Z; Yin Y; Lan M; Lou K; Zhao Y; Yang Y; Chen X; Gao F
Mol Pharm; 2020 Jan; 17(1):301-315. PubMed ID: 31765570
[TBL] [Abstract][Full Text] [Related]
15. Growth Retardation of Poorly Transfectable Tumor by Multiple Injections of Plasmids Encoding PE40 Based Targeted Toxin Complexed with Polyethylenimine.
Khodarovich Y; Rakhmaninova D; Kagarlitskiy G; Baryshnikova A; Deyev S
Curr Gene Ther; 2020; 20(4):289-296. PubMed ID: 32807050
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells.
Fong V; Osterbur M; Capella C; Kim YE; Hine C; Gorbunova V; Seluanov A; Dewhurst S
PLoS One; 2011; 6(12):e28714. PubMed ID: 22174876
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.
Intra J; Salem AK
J Control Release; 2008 Sep; 130(2):129-38. PubMed ID: 18538436
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
19. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers.
Smaldone MC; Davies BJ
Curr Opin Mol Ther; 2010 Oct; 12(5):607-16. PubMed ID: 20886393
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
